| **Eligibility Term**                                 | **Cancer Type** | **Category**      | **% of Trials (in category)** | **Inclusion/Exclusion** | **FHIR Resource**   | **Code (LOINC/SNOMED/ICD)** | **Unstructured EMR Example**                     |
| ---------------------------------------------------- | --------------- | ----------------- | ----------------------------- | ----------------------- | ------------------- | --------------------------- | ------------------------------------------------ |
| ECOG Performance Status ≤ 1 or 2                     | Lung Cancer     | Clinical          | 100%                          | Inclusion               | Observation         | LOINC: 89243-0              | ECOG score was 1 on baseline report              |
| Histologically or cytologically confirmed NSCLC      | Lung Cancer     | Diagnosis         | 100%                          | Inclusion               | Condition           | SNOMED: 254637007           | Biopsy confirmed adenocarcinoma of the lung      |
| Stage IV NSCLC (squamous or non-squamous)            | Lung Cancer     | Diagnosis         | 93.3%                         | Inclusion               | Condition           | ICD-10: C34.x               | Diagnosed with Stage IV NSCLC via PET-CT         |
| Measurable disease per RECIST 1.1                    | Lung Cancer     | Imaging           | 86.7%                         | Inclusion               | Observation         | SNOMED: 371861004           | CT scan revealed lesion measurable under RECIST  |
| No prior systemic therapy for advanced NSCLC         | Lung Cancer     | Treatment History | 80%                           | Inclusion               | Procedure           | SNOMED: 410942007           | No record of systemic chemotherapy               |
| PD-L1 testing available                              | Lung Cancer     | Pathology         | 60%                           | Inclusion               | Observation         | LOINC: 85337-4              | PD-L1 IHC showed 65% expression                  |
| EGFR-sensitizing mutation exclusion                  | Lung Cancer     | Genetic           | 46.7%                         | Exclusion               | Observation         | LOINC: 92822-6              | EGFR L858R mutation detected in genomic report   |
| Untreated CNS metastases                             | Lung Cancer     | Imaging           | 73.3%                         | Exclusion               | Condition           | ICD-10: C79.31              | Brain MRI showed active metastatic lesion        |
| ALK translocation exclusion                          | Lung Cancer     | Genetic           | 33.3%                         | Exclusion               | Observation         | LOINC: 81248-5              | ALK positive via FISH analysis                   |
| History of autoimmune disease                        | Lung Cancer     | Medical History   | 66.7%                         | Exclusion               | Condition           | SNOMED: 64572001            | Past medical history includes lupus              |
| Positive HIV test                                    | Lung Cancer     | Infection         | 60%                           | Exclusion               | Observation         | LOINC: 56888-1              | HIV status: Positive in serology report          |
| Active Hepatitis B or C                              | Lung Cancer     | Infection         | 60%                           | Exclusion               | Observation         | LOINC: 5195-3 / 20416-4     | Hepatitis B surface antigen: positive            |
| Life expectancy ≥ 3 months                           | Lung Cancer     | Clinical          | 46.7%                         | Inclusion               | Observation         | SNOMED: 397709008           | Oncologist estimates >3 month survival           |
| Prior treatment with PD-1/PD-L1 inhibitors           | Lung Cancer     | Treatment History | 53.3%                         | Exclusion               | Procedure           | SNOMED: 428341000124102     | Received nivolumab in past                       |
| Adequate organ function                              | Lung Cancer     | Lab               | 93.3%                         | Inclusion               | Observation         | LOINC Panel                 | Creatinine, AST/ALT, WBC within limits           |
| No prior chemotherapy for metastatic NSCLC           | Lung Cancer     | Treatment History | 73.3%                         | Inclusion               | Procedure           | SNOMED: 371533000           | No chemotherapy recorded post-stage IV diagnosis |
| Negative pregnancy test (females)                    | Lung Cancer     | Reproductive      | 53.3%                         | Inclusion               | Observation         | LOINC: 19080-1              | Urine HCG test: Negative                         |
| Use of contraception during and after study          | Lung Cancer     | Reproductive      | 66.7%                         | Inclusion               | Observation         | SNOMED: 243796009           | Advised to continue contraceptives for 180 days  |
| No prior immunotherapy (e.g., checkpoint inhibitors) | Lung Cancer     | Treatment History | 46.7%                         | Inclusion               | Procedure           | SNOMED: 18286008            | Immunotherapy history: none                      |
| Active autoimmune condition needing systemic therapy | Lung Cancer     | Medical History   | 46.7%                         | Exclusion               | Condition           | SNOMED: 69896004            | Patient has Crohn’s disease on steroids          |
| ILD or pneumonitis history                           | Lung Cancer     | Respiratory       | 40%                           | Exclusion               | Condition           | SNOMED: 67782005            | HRCT shows fibrosis suggestive of ILD            |
| Recent major surgery (<4 weeks)                      | Lung Cancer     | Surgery           | 33.3%                         | Exclusion               | Procedure           | SNOMED: 387713003           | Surgery completed 3 weeks ago                    |
| Active infection requiring IV therapy                | Lung Cancer     | Infection         | 26.7%                         | Exclusion               | Condition           | SNOMED: 87628006            | Admitted for IV antibiotics for pneumonia        |
| EGFR Exon 19 deletion or L858R required              | Lung Cancer     | Genetic           | 26.7%                         | Inclusion               | Observation         | LOINC: 85183-2              | EGFR exon 19 deletion detected                   |
| Prior radiation >30 Gy to lungs                      | Lung Cancer     | Treatment History | 20%                           | Exclusion               | Procedure           | SNOMED: 122471000119102     | Prior thoracic RT of 35 Gy                       |
| No active second malignancy (last 5 years)           | Lung Cancer     | Diagnosis         | 53.3%                         | Exclusion               | Condition           | SNOMED: 399981008           | Prior cancer history: prostate (cured)           |
| No live vaccines 30 days prior                       | Lung Cancer     | Immunization      | 26.7%                         | Exclusion               | Procedure           | SNOMED: 33879002            | Received MMR vaccine 15 days before screening    |
| QTc ≤ 470 ms                                         | Lung Cancer     | Cardiac           | 26.7%                         | Inclusion               | Observation         | LOINC: 8649-2               | ECG shows QTc of 460 ms                          |
| Symptomatic or unstable CNS metastases               | Lung Cancer     | Neurologic        | 33.3%                         | Exclusion               | Condition           | SNOMED: 312912007           | Brain MRI: active lesion with edema              |
| No investigational drug in last 4 weeks              | Lung Cancer     | Treatment History | 40%                           | Exclusion               | Procedure           | SNOMED: 429457009           | Enrolled in drug trial 2 weeks prior             |
| No prior ALK-TKI therapy                             | Lung Cancer     | Treatment History | 20%                           | Exclusion               | Procedure           | SNOMED: 432137009           | Never received crizotinib                        |
| RET fusion-positive tumor                            | Lung Cancer     | Genetic           | 6.7%                          | Inclusion               | Observation         | LOINC: 81286-5              | RET rearrangement detected in NGS report         |
| Measurable tumor per imaging                         | Lung Cancer     | Imaging           | 86.7%                         | Inclusion               | Observation         | SNOMED: 36971009            | CT: Lesion >10 mm in RUL                         |
| Recovery from prior therapy/surgery                  | Lung Cancer     | Treatment History | 40%                           | Inclusion               | Procedure           | SNOMED: 304527002           | Recovered from lobectomy 3 weeks prior           |
| Stable treated CNS metastases                        | Lung Cancer     | Imaging           | 33.3%                         | Inclusion               | Condition           | SNOMED: 422504002           | Brain metastases treated and resolved            |
| Prior hypersensitivity to monoclonal antibodies      | Lung Cancer     | Allergy           | 33.3%                         | Exclusion               | Condition           | SNOMED: 294967001           | Documented reaction to bevacizumab               |
| Chronic systemic steroid use                         | Lung Cancer     | Medication        | 33.3%                         | Exclusion               | MedicationStatement | RxNorm: 8610                | Prednisolone 10 mg daily for 2 months            |
| Squamous histology exclusion (some trials)           | Lung Cancer     | Pathology         | 20%                           | Exclusion               | Observation         | SNOMED: 399919001           | Histology: squamous cell carcinoma               |
| Inadequate renal function                            | Lung Cancer     | Lab               | 26.7%                         | Exclusion               | Observation         | LOINC: 2160-0               | Creatinine clearance < 30 ml/min                 |
| Hepatitis B surface antigen positive                 | Lung Cancer     | Infection         | 40%                           | Exclusion               | Observation         | LOINC: 5195-3               | HBsAg test: reactive                             |
| Tumor tissue availability for testing                | Lung Cancer     | Pathology         | 53.3%                         | Inclusion               | Specimen            | SNOMED: 119294006           | FFPE tumor block submitted for analysis          |
| Use of strong CYP3A4 inducers                        | Lung Cancer     | Medication        | 26.7%                         | Exclusion               | MedicationStatement | RxNorm: 1049626             | Taking rifampin for TB                           |
| Severe cardiovascular disease                        | Lung Cancer     | Medical History   | 33.3%                         | Exclusion               | Condition           | SNOMED: 49601007            | Congestive heart failure (NYHA Class III)        |
| Organ transplant history                             | Lung Cancer     | Medical History   | 13.3%                         | Exclusion               | Procedure           | SNOMED: 67166004            | Kidney transplant in 2012                        |
| Pregnant or breastfeeding                            | Lung Cancer     | Reproductive      | 60%                           | Exclusion               | Observation         | SNOMED: 77386006            | Pregnancy confirmed via urine HCG                |
| Non-childbearing potential (female)                  | Lung Cancer     | Reproductive      | 26.7%                         | Inclusion               | Observation         | SNOMED: 434481000124105     | Post-menopausal, not at risk of pregnancy        |
| Inadequate hematologic function                      | Lung Cancer     | Lab               | 46.7%                         | Exclusion               | Observation         | LOINC Panel                 | WBC < 3.0, Hb < 9.0                              |
| Major surgery within 3–4 weeks                       | Lung Cancer     | Surgery           | 46.7%                         | Exclusion               | Procedure           | SNOMED: 387713003           | Lobectomy performed 2 weeks ago                  |
| Need for concurrent anticancer therapy               | Lung Cancer     | Treatment History | 26.7%                         | Exclusion               | Procedure           | SNOMED: 385763009           | Required radiation during trial period           |
| Hypersensitivity to platinum compounds               | Lung Cancer     | Allergy           | 13.3%                         | Exclusion               | Condition           | SNOMED: 294968006           | Allergic to carboplatin                          |
| Interstitial Lung Disease (ILD) history              | Lung Cancer     | Pulmonary         | 46.7%                         | Exclusion               | Condition           | SNOMED: 233604007           | ILD noted in prior CT scan and medical records   |
| Radiation pneumonitis history                        | Lung Cancer     | Pulmonary         | 26.7%                         | Exclusion               | Condition           | SNOMED: 199006007           | Fibrosis from prior chest radiation present      |
| No EGFR or ALK mutation                              | Lung Cancer     | Genetic           | 26.7%                         | Exclusion               | Observation         | LOINC: 69548-6              | EGFR mutation: negative                          |
| PD-L1 status known (IHC)                             | Lung Cancer     | Biomarker         | 40%                           | Inclusion               | Observation         | LOINC: 85337-4              | Tumor PD-L1 TPS: 50%                             |
| Active Hepatitis C infection                         | Lung Cancer     | Infection         | 40%                           | Exclusion               | Observation         | LOINC: 13955-0              | HCV RNA positive                                 |
| Prior docetaxel therapy                              | Lung Cancer     | Treatment History | 13.3%                         | Exclusion               | Procedure           | SNOMED: 440376006           | Treated with docetaxel in prior regimen          |
| Recent systemic infection (last 4 weeks)             | Lung Cancer     | Infection         | 26.7%                         | Exclusion               | Condition           | SNOMED: 87628006            | Hospitalized for sepsis 3 weeks ago              |
| Refractory nausea/vomiting                           | Lung Cancer     | GI                | 13.3%                         | Exclusion               | Condition           | SNOMED: 28944009            | Nausea uncontrolled by medication                |
| Impaired drug absorption (GI disorders)              | Lung Cancer     | GI                | 20%                           | Exclusion               | Condition           | SNOMED: 7163003             | Crohn’s disease affecting absorption             |
| Severe liver impairment                              | Lung Cancer     | Lab               | 13.3%                         | Exclusion               | Observation         | LOINC Panel                 | ALT/AST > 3× ULN                                 |
| Blood transfusion requirement                        | Lung Cancer     | Clinical          | 6.7%                          | Exclusion               | Procedure           | SNOMED: 46705006            | Receiving packed red cells weekly                |
| Unable to swallow oral medications                   | Lung Cancer     | Clinical          | 13.3%                         | Exclusion               | Observation         | SNOMED: 162057007           | Patient has dysphagia from esophageal mass       |
| Performance Status WHO 0–1                           | Lung Cancer     | Clinical          | 26.7%                         | Inclusion               | Observation         | SNOMED: 443761000124104     | WHO PS recorded as 0                             |
| Tumor PD-L1 ≥ 50%                                    | Lung Cancer     | Biomarker         | 13.3%                         | Inclusion               | Observation         | LOINC: 85337-4              | IHC shows TPS score of 70%                       |
| Prior checkpoint inhibitor use                       | Lung Cancer     | Treatment History | 26.7%                         | Exclusion               | Procedure           | SNOMED: 433144002           | Received nivolumab in past 6 months              |
| Anti-PD-1/PD-L1/PD-L2 exposure                       | Lung Cancer     | Treatment History | 33.3%                         | Exclusion               | Procedure           | SNOMED: 433144002           | History of pembrolizumab use                     |
| Asymptomatic CNS metastases allowed                  | Lung Cancer     | Neurologic        | 13.3%                         | Inclusion               | Condition           | SNOMED: 312912007           | Brain lesion stable on follow-up MRI             |
| No symptomatic bradycardia                           | Lung Cancer     | Cardiac           | 6.7%                          | Exclusion               | Observation         | LOINC: 8867-4               | Heart rate: 40 bpm, dizziness reported           |
| Prior platinum-based chemotherapy                    | Lung Cancer     | Treatment History | 33.3%                         | Inclusion               | Procedure           | SNOMED: 4471000126108       | Treated with cisplatin + pemetrexed              |
| Resected Stage IB–IIIA NSCLC                         | Lung Cancer     | Diagnosis         | 13.3%                         | Inclusion               | Condition           | SNOMED: 254637007           | Surgical pathology: Stage IIA NSCLC              |
| No unresolved toxicity > Grade 1                     | Lung Cancer     | Clinical          | 13.3%                         | Exclusion               | Observation         | SNOMED: 2741000046100       | Grade 2 neuropathy persisted post-therapy        |
| Immunosuppressive therapy usage                      | Lung Cancer     | Medication        | 20%                           | Exclusion               | MedicationStatement | RxNorm: 8665                | Long-term prednisone use noted                   |
| Prior CD137 agonist exposure                         | Lung Cancer     | Treatment History | 13.3%                         | Exclusion               | Procedure           | SNOMED: 41291007            | Received CD137 antibody in phase I trial         |
| Current or recent drug/alcohol abuse                 | Lung Cancer     | Behavioral        | 26.7%                         | Exclusion               | Condition           | SNOMED: 191816009           | Positive urine screen for cannabis               |
| Inability to comply with protocol                    | Lung Cancer     | Clinical          | 33.3%                         | Exclusion               | Observation         | SNOMED: 27624003            | Cognitive impairment noted, poor compliance      |
| Major surgery within 3–4 weeks                       | Lung Cancer     | Treatment History | 60%                           | Exclusion               | Procedure           | SNOMED: 387713003           | Thoracotomy performed 2 weeks prior              |
| QTc >470 ms or ECG abnormality                       | Lung Cancer     | Cardiac           | 40%                           | Exclusion               | Observation         | LOINC: 77606-2              | QTc interval measured 480 ms                     |
| Pregnancy or lactation                               | Lung Cancer     | Reproductive      | 100%                          | Exclusion               | Observation         | LOINC: 19080-1              | Positive serum pregnancy test                    |
| Use of strong CYP3A inducers/inhibitors              | Lung Cancer     | Medication        | 26.7%                         | Exclusion               | MedicationStatement | RxNorm Group                | Taking ketoconazole regularly                    |
| No live vaccine within 30 days                       | Lung Cancer     | Immunization      | 20%                           | Exclusion               | Immunization        | CVX: 01 (MMR)               | Received yellow fever vaccine 10 days prior      |
| Participation in another trial                       | Lung Cancer     | Treatment History | 40%                           | Exclusion               | ResearchStudy       | SNOMED: 308292007           | On an investigational protocol for melanoma      |
| Grade ≥2 neuropathy                                  | Lung Cancer     | Neurologic        | 13.3%                         | Exclusion               | Observation         | SNOMED: 230686007           | Complains of burning foot pain and numbness      |
| Prior hypersensitivity to study drugs                | Lung Cancer     | Allergy           | 26.7%                         | Exclusion               | AllergyIntolerance  | SNOMED: 294967001           | History of rash with paclitaxel                  |
| Prior EGFR/ALK TKI treatment                         | Lung Cancer     | Treatment History | 20%                           | Exclusion               | MedicationStatement | RxNorm: 398181 (erlotinib)  | Was treated with erlotinib 1 year ago            |
| Tumor sample available for biomarker testing         | Lung Cancer     | Biomarker         | 33.3%                         | Inclusion               | Specimen            | SNOMED: 119376003           | FFPE tumor block sent to central lab             |
| Stable CNS metastases allowed                        | Lung Cancer     | Neurologic        | 20%                           | Inclusion               | Condition           | SNOMED: 312912007           | Brain mets treated 4 weeks ago, stable MRI       |
| Not eligible if squamous histology                   | Lung Cancer     | Diagnosis         | 20%                           | Exclusion               | Condition           | SNOMED: 254637007           | Biopsy shows squamous cell carcinoma             |
| Tumor EGFR activating mutation (Ex19del or L858R)    | Lung Cancer     | Genetic           | 33.3%                         | Inclusion               | Observation         | LOINC: 48018-6              | EGFR exon 19 deletion present                    |
| Use of systemic corticosteroids                      | Lung Cancer     | Medication        | 33.3%                         | Exclusion               | MedicationStatement | RxNorm: 1049220             | Prednisone 20mg daily for arthritis              |
| No prior systemic therapy for advanced NSCLC         | Lung Cancer     | Treatment History | 53.3%                         | Inclusion               | Procedure           | SNOMED: 4471000126108       | No chemo/immunotherapy since diagnosis           |
| Significant comorbid illness interfering with study  | Lung Cancer     | Clinical          | 26.7%                         | Exclusion               | Condition           | SNOMED: 162607003           | NYHA Class III CHF noted                         |
| Prior radiation >30 Gy to lungs                      | Lung Cancer     | Treatment History | 40%                           | Exclusion               | Procedure           | SNOMED: 108290001           | Prior RT: 35 Gy to left upper lobe               |
| Pemetrexed ineligibility (e.g., squamous histology)  | Lung Cancer     | Treatment History | 13.3%                         | Exclusion               | Procedure           | SNOMED: 428191000124100     | Cannot receive pemetrexed (squamous histology)   |
| CNS metastases or leptomeningeal disease             | Lung Cancer     | Neurologic        | 33.3%                         | Exclusion               | Condition           | SNOMED: 312912007           | Brain MRI showed leptomeningeal enhancement      |
| Prior allogeneic transplant                          | Lung Cancer     | Treatment History | 13.3%                         | Exclusion               | Procedure           | SNOMED: 430193006           | Allogeneic bone marrow transplant 5 years ago    |
| Immune checkpoint inhibitors not previously received | Lung Cancer     | Treatment History | 26.7%                         | Inclusion               | Procedure           | SNOMED: 433144002           | Patient is immunotherapy-naive                   |
| Female/male contraception commitment                 | Lung Cancer     | Reproductive      | 80%                           | Inclusion               | Observation         | SNOMED: 364703007           | Using IUD and barrier method                     |
| Prior CTLA-4 inhibitor use                           | Lung Cancer     | Treatment History | 13.3%                         | Exclusion               | MedicationStatement | SNOMED: 372729009           | Previously treated with ipilimumab               |
| Symptomatic bradycardia/QT prolongation              | Lung Cancer     | Cardiac           | 13.3%                         | Exclusion               | Observation         | LOINC: 8867-4               | HR: 42 bpm with dizziness noted                  |
| Life expectancy ≥12 weeks                            | Lung Cancer     | Clinical          | 33.3%                         | Inclusion               | Observation         | SNOMED: 75273003            | Oncologist estimates survival >3 months          |
